Work in animals and humans has suggested the existence of a slow wave sleep (SWS)-promoting/electroencephalogram (EEG)synchronizing center in the mammalian lower brainstem. Although sleep-active GABAergic neurons in the medullary parafacial zone (PZ) are needed for normal SWS, it remains unclear whether these neurons can initiate and maintain SWS or EEG slowwave activity (SWA) in behaving mice. We used genetically targeted activation and optogenetically based mapping to examine the downstream circuitry engaged by SWS-promoting PZ neurons, and we found that this circuit uniquely and potently initiated SWS and EEG SWA, regardless of the time of day. PZ neurons monosynaptically innervated and released synaptic GABA onto parabrachial neurons, which in turn projected to and released synaptic glutamate onto cortically projecting neurons of the magnocellular basal forebrain; thus, there is a circuit substrate through which GABAergic PZ neurons can potently trigger SWS and modulate the cortical EEG. npg
A good night's sleep is an established prerequisite for optimal physiologic, psychologic and cognitive function, yet the subcortical brain structures regulating sleep, in particular SWS, and its electroencephalogram correlates remain incompletely understood. One model of sleep-wake regulation posits a flip-flop switching mechanism that involves mutually inhibitory interactions between sleep-promoting neurons in the ventrolateral preoptic area (VLPO) and wake-promoting neurons in the brainstem and hypothalamus 1, 2 . Although this model has heuristic value for understanding the neurobiology of sleep and its disorders, it does not fully account for data derived from early neurophysiologic and transection experiments in animals [3] [4] [5] and more recent human-based functional magnetic resonance imaging (fMRI) studies 6 that have suggested the existence of a SWS-promoting/EEG synchronizing center in the lower brainstem of mammals. Although animals with lesions of the VLPO show a marked (~40-50%) and sustained increase in waking, about half of the normal behavioral and electrographic SWS remains 7 , indicating that additional circuitry for promoting SWS must exist. The intensity of cortical SWA (0.5-4 Hz) during SWS is also widely accepted as a reliable indicator of sleep need, is thought to mediate the general restorative function of sleep 8, 9 , and is thought to be involved in memory consolidation 10 , synaptic homeostasis 11 and other aspects of cortical plasticity 12 . Thus, elucidating the location and identity of extra-VLPO neurons that generate SWS and cortical SWA remains central to our understanding of not only brain sleep per se, but also many sleep-dependent neurobiological processes. Toward this end, it was recently reported that sleep-active GABAergic neurons in the medullary PZ are needed for normal SWS 13 . However, it remains unclear whether these neurons are capable of driving SWS or EEG SWA in intact animals and how these putative SWS-promoting PZ neurons may be functionally and synaptically coupled with more rostrally situated circuitry capable of influencing the cortical EEG.
RESULTS

PZ GABAergic neurons promote SWS in behaving mice
To test the ability of GABAergic PZ neurons to initiate SWS in behaving animals ( Fig. 1) , we bilaterally injected an adeno-associated viral (AAV) vector containing an excitatory modified muscarinic G proteincoupled receptor (DIO-hM3Dq-mCherry-AAV10; Fig. 1b ) expressed in a Cre-dependent manner into the PZ (Fig. 1a,b, Fig. 1 ) of Vgat-IRES-cre mice 14 (Fig. 1c-e ) and non-Cre-expressing littermates. Robust cell-surface expression of the hM3Dq receptors was observed on GABAergic PZ neurons of Vgat-IRES-cre mice ( Fig. 1f,g) , but was absent in non-Cre-expressing littermates, confirming the requirement for Cre activity to enable hM3Dq expression in PZ GABAergic neurons. Injections of the hM3Dq agonist clozapine-Noxide (CNO, 0.3 mg per kg of body weight, intraperitoneal (IP)), which is otherwise pharmacologically inert, also drove c-Fos expression in hM3Dq-expressing GABAergic neurons in the PZ (Fig. 1h) , confirming ligand-induced activation of hM3Dq-expressing GABAergic PZ neurons in vivo. CNO-driven depolarization and firing of hM3Dqexpressing GABAergic PZ neurons was also confirmed in whole-cell, current-clamp recordings (Fig. 1i) . Notably, in baseline condition, we observed no differences between Vgat-IRES-cre mice expressing hM3Dq in GABAergic PZ neurons and non-hM3Dq-expressing littermate mice in hourly sleep-wake or the EEG power spectra ( Supplementary Fig. 2 and Supplementary Table 1 ), demonstrating that, in the absence of the ligand (CNO), hM3Dq receptors had no a r t I C l e S effect on sleep-wake parameters. Similarly, IP injections of CNO had no effect on these same parameters in non-hM3Dq-expressing mice ( Supplementary Fig. 3 and Supplementary  Table 2 ), indicating that the electrographic or physiologic changes observed in hM3Dqexpressing mice following CNO administration are directly linked to the activation of PZ GABAergic neurons.
f,g and Supplementary
Following IP vehicle injections at 7 p.m. (lights off), mice expressing the hM3Dq receptor in GABAergic PZ neurons displayed a typical night hypnogram, with long bouts of wakefulness marked by high electromyogram (EMG) activity and low EEG SWA ( Figs. 2 and 3) . Following IP CNO injections, however, mice fell asleep with a short latency ( Fig. 3b and Supplementary Table 2 ) and SWS, marked by low EMG activity and high EEG SWA (Fig. 2b,c) , was significantly increased during the 3-h post-injection period as compared with vehicle (P < 0.0001; Fig. 3b and Supplementary Table 2 ). SWS bout length was also significantly increased during the 3-h post-CNO injection period (P < 0.001; Supplementary Table 2) , indicative of a consolidated CNO-induced SWS. More specifically, when SWS was analyzed as a function of bout length for baseline or vehicle injection conditions, the preponderance of SWS occurred in 1-10-min bouts, with no bouts exceeding 20 min. (Fig. 3e) . Following administration of CNO, however, the preponderance of SWS occurred in bouts longer than 5 min, and ~35% of the SWS amount occurred in bouts longer than 20 min.
The SWS EEG was also enriched with SWA during the first hour of CNO-induced SWS as compared with SWS following vehicle injection ( Figs. 2b and 3c and Supplementary Fig. 4 ). By contrast, higher frequencies, such as beta and gamma, were decreased. Given that SWA is a widely accepted marker of SWS quality and intensity 9, 15, 16 and high EEG frequencies are indicative of cortical activation and wakefulness 17 , our findings suggest that GABAergic PZ neurons can influence both the quantitative and qualitative aspects of SWS. SWS delta power is typically maximal during the dark period, following long, consolidated bouts of wakefulness. Notably, activation of PZ GABAergic neurons by CNO resulted in higher SWS delta power than the maximum observed during time-of-day equivalent spontaneous sleep in these mice. The same was true when CNO injections were performed during the light period ( Fig. 4) , which is a time of high 'sleep drive' in mice. Even more notably, activation of PZ GABAergic neurons by CNO during the normal sleeping period increased SWS amount and bout lengths beyond the maximum observed during time-of-day equivalent spontaneous sleep ( Fig. 4b,e and Supplementary npg a r t I C l e S elevated SWA observed after activation of PZ GABAergic neurons is similar to the sleep rebound observed following sleep deprivation. Furthermore, the deep SWS induced by CNO administration appeared to satisfy the homeostatic need for sleep for the remainder of the dark period ( Fig. 2b) . Consistent with our behavioral and EEG findings, CNO administration produced a marked reduction in cortical c-Fos ( Supplementary Fig. 5 ), indicative of a quiescent cellular cortex. Finally, acute and selective silencing of PZ GABAergic neurons at 10 a.m. (a time of high sleep pressure in the mouse), which we achieved using a Cre-enabled inhibitory modified muscarinic G protein-coupled receptor (DIO-hM4Di-mCherry-AAV10), strongly decreased the percentage of time spent in SWS over a 2-h post-CNO injection period as compared with vehicle injections (Supplementary Fig. 6 ). Thus, and consistent with our previous findings, PZ GABAergic neurons also appear to be necessary for the initiation of normal SWS, even during times of high sleep drive. npg a r t I C l e S CNO-induced SWS occurred at the expense of both wake and rapid eye movement (REM) sleep, which were significantly decreased 3 and 9 h, respectively, following CNO administration (P < 0.0001; Fig. 3a,d) . During the 3-h post-CNO injection period, wake bout duration was decreased as compared with vehicle injections. Specifically, the preponderance of wake amount occurred in 10-s to 10-min bouts following CNO administration, whereas most wake amount occurred in bouts 10 min or longer following vehicle injections ( Fig. 3e) . During the remaining hours of the active (dark) period, and unlike that observed following the daytime CNO injections ( Fig. 4a) , wake amount was significantly increased between 10 p.m. and 7 a.m. (P < 0.01; Fig. 3a ), suggesting that wake, similar to sleep, may also be under some level of homeostatic regulation, that is, a wake rebound. With respect to REM sleep, its latency was significantly increased (P < 0.0001; Fig. 3d and Supplementary Table 2 ) and REM sleep amount remained significantly decreased over the remaining hours of the active period following CNO injection (P < 0.0001; Fig. 3d ). During the subsequent light period, REM sleep amount returned to control levels and no REM sleep rebound was seen, resulting in a net and significant decrease in REM sleep amount over the 24 h following CNO injection (46.6 ± 7.4 versus 72.8 ± 5.3 min after vehicle injection, P = 0.0028, n = 13). Given that SWS and wake homeostasis generally takes precedence over that of REM sleep, we also analyzed REM sleep on the second night following the 7 p.m. CNO injections, but still found no evidence of REM recovery (Supplementary Table 2 ).
PZ directly inhibits BF-projecting PB neurons
Previously, we found that PZ sleep-active neurons project to the wake-promoting parabrachial nucleus (PB) 13 . Given that projections from glutamatergic PB neurons to the magnocellular basal forebrain (BFmc), but not the thalamus, are indispensable for maintaining cortical activation and wakefulness 18, 19 , we hypothesized that GABAergic PZ neurons might promote SWS and SWA by inhibiting the wakepromoting PB-BFmc-cortex circuit. In other words, we predicted that PZ GABAergic neurons monosynaptically project to and produce inhibitory postsynaptic events in PB neurons that specifically and monosynaptically innervate neurons of the BFmc. To test this hypothesis, we injected a Cre-dependent vector containing channelrhodopsin-2 (DIO-ChR2(H134R)-mCherry-AAV; ChR2-mCherry) into the PZ and retrograde fluorescent microspheres into the ipsilateral BFmc npg a r t I C l e S of Vgat-IRES-cre mice ( Fig. 5a ). Histological assessment confirmed accurate bead placement in the BF ( Fig. 5b-d ) and that mCherrypositive somas were restricted to the GABAergic PZ (PZ Vgat ; Fig. 5e,f) . Photo-stimulation of PZ Vgat cell bodies expressing ChR2-mCherry elicited robust photocurrents, and trains of brief blue-light flashes entrained the firing of PZ Vgat neurons up to 5 Hz (Supplementary Fig. 7) .
To determine whether activation of PZ axons evoked GABA release in the PB, we photo-stimulated PB slices containing ChR2-mCherryexpressing axons that originated from PZ Vgat neurons. The flashes of blue light evoked fast inhibitory postsynaptic currents (IPSCs) in PB neurons that were retrogradely labeled from the BFmc (n = 7 of 18 neurons). The light stimuli induced synaptic events with amplitude comparable to those of spontaneous IPSCs, indicating that the responses were in the physiological range. Moreover, based on the rapid kinetics, both the spontaneous and photo-evoked responses occurred in the soma and proximal dendrites of the cell. The photoevoked IPSCs were also completely abolished by bicuculline (20 µM; Fig. 5g,h) , indicating that these responses were mediated by the release of GABA and by the activation of GABA A postsynaptic receptors. In BFmc-projecting PB neurons that exhibited synaptic responses (PZ Vgat →PB), the probability of any given light pulse evoking a synchronous IPSC was 58.0 ± 5.6% (n = 7; Fig. 5i,j) . Three stimuli were used to show that the response was consistent across stimulation and that no depression occurred following repeated stimulation, that is, individual synaptic response had equivalent amplitudes. The photoevoked IPSCs in PB neurons projecting to BFmc had an average onset delay of 6.2 ± 0.3 ms, a peak amplitude of 23.1 ± 3.2 pA and a charge transfer of 1.02 ± 0.21 pC (single light pulses, n = 7). Photo-stimulation evoked IPSC's in PB neurons even in the presence of tetrodotoxin (TTX, n = 4; Fig. 5k ), supporting a direct synaptic connectivity from PZ to PB (PZ Vgat →PB→BFmc).
Given that neurons of the BFmc directly and heavily innervate the cerebral cortex (most regions and layers) 20 , we sought to confirm, using a similar approach to the foregoing, that glutamatergic PB neurons monosynaptically project to and produce excitatory postsynaptic responses in cortically projecting BF neurons. To do so, we placed injections of ChR2-mCherry into the lateral PB and retrograde fluorescent microspheres into the ipsilateral prefrontal cortex (PFC) of Vglut2-IRES-cre mice (n = 3; Fig. 5l ). Histological assessment confirmed accurate bead placement in the PFC and mCherry-positive somas restricted to the glutamatergic lateral PB (Fig. 5m,n) . To determine whether activation of PB axons evoked glutamate release npg a r t I C l e S in BFmc neurons that were retrogradely labeled from the PFC, we photo-stimulated slices containing ChR2-mCherry-expressing axons that originated from PB Vglut2 neurons. The flashes of blue light evoked action potential firing and short-latency excitatory postsynaptic currents (EPSCs) in cortically projecting neurons of the BFmc (6 of 7 neurons, average onset delay = 5.9 ± 0.6 ms, n = 4), suggesting a direct synaptic connectivity from PB to BFmc (PB Vglut2 →BFmc→ PFC). Responses to photo-stimulation in BFmc neurons were completely abolished by 6,7-dinitroquinoxaline-2,3-dione (DNQX, 30 µM; Fig. 5o-q) , indicating that these responses were mediated by the release of glutamate and by the activation of AMPA postsynaptic receptors. In summary, GABAergic PZ neurons monosynaptically innervate and release synaptic GABA onto PB neurons, which in turn project to and release synaptic glutamate onto cortically projecting neurons of the BFmc. Thus, the PZ Vgat →PB Vglut2 →BFmc→PFC circuit represents a functional circuit substrate through which PZ GABA neurons can regulate cortical circuitry to potently modulate behavioral state and EEG SWA (Supplementary Fig. 8) .
DISCUSSION
Batini's study 3 in 1958 of the midpontine pretrigeminal preparation, which resulted in chronic insomnia (that is, forebrain desynchrony), inspired the hypothesis that the caudal brainstem contained SWS-promoting/EEG-synchronizing structures 3 . The location and existence of SWS-promoting/EEG-synchronizing circuitry in the mammalian brainstem has, however, remained unresolved. We found, to the best of our knowledge for the first time, that activation of a delimited node of GABAergic neurons located in the medullary PZ could potently initiate SWS and cortical SWA in behaving animals. We further describe a functional, synaptic brainstem-forebrain-cortex pathway through which these neurons can modulate behavioral state and the cortical EEG.
PZ induces physiologic SWS and cortical SWA
There is every indication that the SWS and cortical SWA induced by activation of PZ GABAergic neurons in our experiments is physiologic. First, the power spectral distribution for CNO-induced SWS is identical to that of the 'spontaneous' SWS observed following control injections. Second, as in normal SWS, we observed a gradual, but persistent, decrease in delta power over the course of the SWS episode 21 . Third, as expected of a 'sleeping brain' , c-Fos expression by cortical neurons was quiescent 22 . Finally, a waking rebound was observed following the induction of SWS, indicating that CNO-induced SWS satisfied sleep need. A deeper inspection of the data further suggest that the CNO-induced SWS was, in fact, a higher 'quality' SWS than normal SWS. For example, delta power was higher and SWS bouts were longer than with normal SWS. This is reminiscent of the 'deep' SWS observed following sleep deprivation 23 a r t I C l e S SWS showed decreased power in the beta-gamma (20-60 Hz) band, which, together with increased delta power, is indicative of a high-quality electrographic SWS 25 . In sum, the increase in delta power at a time at which delta is normally maximal (that is, 7 p.m., which is the beginning of the dark period) 9, 16 , the increase in SWS when sleep drive is normally maximal (that is, ZT3), the short latency to SWS following CNO administration, and the length and consolidated nature of the CNO-induced SWS all strongly indicate that activation of PZ GABAergic neurons can rapidly and potently induces physiologic SWS and cortical SWA. Moreover, and consistent with a SWS-promoting function, acute inhibition of PZ GABAergic neurons at a time of day approximating peak sleep drive strongly decreased the percentage time spent in SWS. It is also of interest that CNO-induced SWS at ZT12, which is a time at which the mice are normally highly awake, resulted in an apparent 'wake deprivation' . In other words, following CNO-induced SWS at ZT12, the mice showed a substantially greater amount of wake, indicating a wake 'rebound' . In contrast, no wake rebound was observed following CNO-induced SWS at ZT3, which is a time at which the mice are normally deeply asleep. Unlike wake, sleep deprivation is relatively easy to induce and study, and a homeostatic rebound of sleep following sleep deprivation is a widely accepted phenomenon in the sleep field. Our findings suggest that CNO-induced SWS at ZT12 may have produced a wake deprivation and a subsequent wake rebound, secondary to the induction of high-quality SWS. That we only observed a wake rebound following CNO-induced SWS during the normal waking, but not sleeping, period is further evidence that the wake rebound is directly linked to wake deprivation and is not a nonspecific response to CNO-induced SWS. Rather, we interpret this finding as evidence that wake, similar to sleep, may also be under some level of homeostatic regulation. This interpretation would be consistent with the vital biological role of wake, which is a behavioral state subserving a myriad of biological imperatives, including feeding and reproducing.
Notably, REM sleep was also inhibited during CNO-induced SWS and for a longer period than the apparent CNO-induced SWS effect. Why REM sleep was so strongly inhibited is unclear to us, but one explanation may be that the high SWS pressure followed by the high wake pressure prevented REM generation. This explanation, however, is not entirely consistent with the physiology observed following activation of PZ GABAergic neurons during the daytime. Specifically, following the CNO-induced SWS at ZT3, waking pressure did not appear to be higher, that is, no apparent wake rebound and normal amounts of SWS were observed far sooner than the 9-h REM suppression observed. In addition, a previous study found that lesions of the rat PZ did not affect REM sleep quantity, whereas disruption of GABAergic transmission by PZ neurons in the mouse reduced REM sleep in proportion to SWS 13 . It therefore remains unclear whether PZ GABAergic neurons (or intermingled non-GABAergic PZ neurons) are involved in REM sleep control, and we feel it is premature to assign a role for PZ in REM sleep control. It is also possible that PZ GABAergic neurons may project to and inhibit neurons that regulate the hippocampal and/or cortical EEG features of REM sleep, for example, the precoeruleus region 26 .
GABAergic PZ inhibits a major wake-promoting circuit
We found that PZ GABAergic neurons project to and produce inhibitory postsynaptic events in presumptive wake-promoting PB neurons, which in turn project directly to the BFmc. This finding not only begins to establish a mechanism and substrate through which PZ GABAergic neurons can produce SWS and cortical SWA, but also links the PZ to circuitry previously established to be involved in maintaining wakeful consciousness. For example, the PB→BF pathway is critically involved in EEG activation and wakefulness. Indeed, ablation of the PB or BF results in a coma-like state in rats, suggesting that an intact PB→BF pathway is an absolute requirement for desynchronization of the cortical EEG 18 . And although a PZ→PB projection was established in a previous study 13 , the neuronal phenotype and neurotransmitter used remain to be clarified. We found that PZ GABAergic neurons released synaptic GABA onto BF-projecting PB neurons, suggesting not only a previously unrecognized source of potent inhibitory influence on the PB→BF pathway, but also a circuit substrate through which the PZ can modulate cortical activity. This contention is further supported by our ChR2-assisted mapping experiments, which revealed functional synaptic connectivity between glutamatergic PB neurons and cortically projecting BF neurons. In other words, our optogenetic-based mapping experiments support a circuit model in which activation of the PZ results in inhibition of the PB and hence the loss of excitatory drive to cortically projecting BFmc neurons. The result is a decrease in the fast frequencies that are characteristic of cortical activation and desynchronization and wakefulness, which then directly or indirectly drives the appearance of slow waves and delta waves that are characteristic of cortical synchronization and SWS. Several aspects of this proposed circuit model remain to be tested and it may ultimately be the case that the PZ modulates cortical activity through other or additional ascending pathways and nodes. For now, however, it remains unclear whether the PZ is interconnected with other sleep-and wake-promoting nodes beyond the wake-promoting PB. There are apparently projections to the PZ from hypocretin/orexin neurons in the lateral hypothalamus 27 , but it is not clear whether these contact PZ sleep-promoting neurons. The VLPO apparently does not project to the PZ 28 and vice versa 29 . Thus, how the PZ may interact with other circuit elements of the 'sleep switch' system remains an important area for future investigation. It should be noted that, although our ChR2-based mapping experiments verified the presence of functional synaptic connectivity in the PZ→ PB→BFmc→cortex circuit, future studies will be required to quantify the relative strength of these inputs. For example, the fact that the amplitudes of photo-evoked IPSCs in the PB were similar to those of spontaneous IPSCs might indicate that the PZ provides a relatively low density of synaptic contacts onto individual PB neurons. The extent, however, to which this might reflect the actual density of PZ inputs to the PB, or rather the percentage of PZ neurons transduced by ChR2-AAV or transduction of non-projecting PZ GABAergic neurons, or a combination of both, remains to be determined. It would also raise the question of whether or not PZ→PB input is sufficient to suppress the activity of PB neurons in behaving mice. Future terminal stimulation and occlusion studies will therefore be an important next experimental step and are being actively pursued in our laboratory. We would note, however, that the connectivity rate, which we define as the probability that any given PB neuron is innervated by the ipsilateral PZ, was relatively high (~40%) and hence PZ-mediated inhibition of the wake-promoting PB remains a likely mechanistic basis for the initiation of SWS and cortical SWA.
It similarly remains unclear whether the forebrain VLPO and the hindbrain PZ operate with any synergy to generate whole-brain sleep. The SWS phenotype that develops following lesions of these structures are different, which suggest divergent roles for the VLPO and PZ in SWS regulation. Specifically, both VLPO and PZ lesions result in a ~50% decrease in daily SWS, yet the reduction in SWS after VLPO or PZ lesions derives from fundamentally different changes in SWS architecture. In the case of VLPO lesions, it is the duration of SWS a r t I C l e S episodes that is reduced 30 , whereas, in the case of PZ lesions, it is the number of SWS episodes that is reduced 13 . To us, these differences suggest that the VLPO may be more critically involved in SWS consolidation, whereas the PZ is more critically involved in SWS initiation, although the extent to which the continued activity of PZ GABAergic neurons may contribute to the duration of the initiated SWS bout remains unknown. Regardless, future studies on animals with both VLPO and PZ lesions or dual activation/inactivation studies will help to clarify the extent to which the VLPO and PZ may work synergistically or function redundantly in the production of SWS.
It is also worth mention that work reaching back many decades has suggested that the nucleus of the solitary tract (NTS) may comprise, at least in part, a SWS-promoting brainstem node 5, 31 . Although the NTS has the ability to modulate cortical activity, and our results do not preclude a SWS-promoting role for the NTS, there exist no data showing that NTS lesions produce insomnia or that they increase the amount of time spent awake [31] [32] [33] [34] [35] , whereas PZ lesions do 13 . The PZ is, in fact, along the outflow tract from the NTS and may receive its input; thus, the PZ may, in addition to regulating the amount of SWS, serve as a link in an ascending pathway (vagal→NTS→PZ) that promotes sleep following, for example, a heavy meal, that is, postprandial somnolence.
In conclusion, we found that all polygraphic and neurobehavioral manifestation of SWS, including SWA, could be initiated in behaving animals by the selective activation of a delimited node of GABAergic medullary neurons. Our findings also suggest a synaptic brainstemforebrain pathway through which these GABAergic PZ neurons can potently modulate behavioral state and cortical activity and which may provide a structural basis for how brainstem inputs ( Supplementary  Fig. 8) , including those that are activated by vagal nerve stimulators used to control epilepsy, may affect the forebrain EEG 36 . These findings contribute to our understanding of how the brain regulates and organizes cycles of sleep-wake and may inform the development of drugs to better regulate states of sleep and wakefulness in patients with sleep or neurological disorders. Our results also provide a new and potentially useful model system for the study of the SWS state and its regulation, as well as for understanding the role of SWS in a continuum of physiologic and neurobiologic processes that SWS has been linked with, including energy metabolism, cognition, learning and cortical plasticity.
METhODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
ONLINE METhODS
Animals. Adult male Vgat-IRES-cre and Vglut2-IRES-cre (129/C57/FVB) mice 37 and non-Cre-expressing littermate mice (8-12 weeks, 20-25 g, n = 29 in vivo and n = 17 in vitro) were used in this study. Mice were bred at our animal facility and underwent genotyping both before and after experiments and all procedures were approved by the Institutional Animal Care and Use Committee of Beth Israel Deaconess Medical Center.
Surgery. Naive mice were anesthetized with ketamine/xylazine (100 and 10 mg per kg, respectively, IP) and then placed in a stereotaxic apparatus. To selectively express the hM3Dq or hM4Di receptors in GABAergic (VGAT + ) neurons of the PZ, we placed bilateral injections of an AAV vector (serotype 10) expressing the hM3Dq or the hM4Di receptor in a Cre-dependent configuration (hSyn-DIO-hM3D-mCherry-AAV or hSyn-DIO-hM4D-mCherry-AAV) into the PZ (coordinates: AP = −5.3 mm, L = ±0.7 mm, DV = −3.4 mm, as per ref. 38) of Vgat-IRES-cre mice (n = 13 injected with AAV-hM3Dq and n = 7 injected with AAV-hM4Di). As vector injection controls, we injected the same viral vector into the PZ of non-Cre-expressing littermate mice (n = 12). Injections of the viral vector (60-300 nl) into the PZ of these mice were performed using a compressed air delivery system as previously described 39 . After injections, mice were implanted with four EEG screw electrodes (Pinnacle Technology) and two flexible EMG wire electrodes (Plastics One), previously soldered to a 6-pin connector (Pinnacle Technology Inc.) and the assembly was secured with dental cement. The scalp wound was closed with surgical sutures and the mouse was kept in a warm environment until resuming normal activity as previously described 40, 41 .
Sleep-wake monitoring. 3 weeks after surgery, the mice were housed individually in transparent barrels in an insulated soundproofed recording chamber maintained at an ambient temperature of 22 ± 1 °C and on a 12-h light/dark cycle (lights-on at 7 a.m.) with food and water available ad libitum. Mice were habituated to the recording cable for 5-7 d before starting polygraphic recording. Cortical EEG (ipsilateral frontoparietal leads) and EMG signals were amplified and digitalized with a resolution of 400 or 500 Hz using PAL 8500 software (Pinnacle Technology) or Vital recorder (Kissei) respectively. Mice were recorded for a 24-h baseline period followed by injections of CNO (Sigma-Aldrich, 0.3 mg per kg in saline, IP) injections at 7 p.m. (lights-off, time of high waking drive) and at 10 a.m. (light period, time of high sleeping drive). As an injection control mice were injected with saline at 10 a.m. and 7 p.m. CNO and saline injections were performed in a random sequence and separated by a 3-5-d washout period. Mice recordings (baseline, saline and CNO injections) were performed four at a time and each time included two PZ hM3Dq-expressing mice and two non-hM3Dq-expressing littermate mice. The injections were performed using a crossover design.
hm3dq-AAV, hm4di and cno. For our in vivo activation studies, we employed an evolved G protein-coupled muscarinic receptor (hM3Dq or hM4Di) that is selectively activated or inhibited by the pharmacologically inert and orally bioavailable drug CNO. This system was developed and described previously 42 . In our studies, a Cre-dependent version of the hM3Dq or hM4Di receptor was packaged into an AAV to facilitate the stereotaxic-based delivery and regionally restricted expression of hM3Dq or hM4Di. As demonstrated by others and confirmed on sleep-wake parameters, both the hM3Dq and hM4Di receptor and its ligand were biologically inert in isolation. It is also the case that no specific role is postulated for cholinergic receptors in PZ neurons; instead, the hM3Dq system renders the PZ GABAergic neurons specifically and uniquely sensitive to the CNO ligand.
Sleep scoring and analysis. Using SleepSign for Animal (Kissei) and with the assistance of spectral analysis using FFT, polygraphic records were visually scored by 10-s epochs for wakefulness, SWS and REM sleep 43, 44 . The percentage of time spent in wake, SWS and REM sleep, as well as the number and the average durations of the episode were summarized for each group and each condition. The latency to SWS and REM sleep are defined as the time between the end of the injection and the onset of the first SWS episode lasting >20 s and the first REM sleep episode lasting >10 s. Recordings were scored again in 4-s epochs to allow for performance of an EEG power spectrum analysis. On the basis of visual and spectral analysis, epochs containing artifacts occurring during active wake (with large movements) or containing two vigilance states were visually identified and omitted from the spectral analysis. Recordings containing wake artifact during more than 20% of the time were removed from the spectral analysis. EEG power spectra were computed for consecutive 4-s epochs in the frequency range of 0.4-59.8 Hz using a FFT routine. The data were collapsed into 0.4-Hz bins. To assess the involvement of hM3Dq receptor expression in sleep-wake power spectra, baseline EEG power spectra were analyzed between 7 p.m. and 1 a.m. The data were standardized by expressing each frequency bin as a percentage relative to the total power (for example, bin power/0.4-59.8 Hz total power) of the same epochs. To analyze the EEG frequency bands, relative power bins were summed in δ 0.4-4.3 Hz, θ 4.3-9.8 Hz, α 9.8-19.9 Hz, β + γ 19.9-59.8 Hz. To determine the effect of CNO injection on sleep-wake power spectra of non-Cre-expressing controls and PZ hM3Dq or hM4Di receptor expressing mice, EEG power spectra were analyzed during the 3-h period of time post injection of vehicle or CNO, starting 10 min after injection, as CNO injection significantly affects SWS amount during 3-h post-injection and SWS latency is no more than 10 min. The data were standardized by expressing each frequency bin as a percentage relative to the same bin in baseline condition from the same mouse and from the same time of the day. To analyze the EEG frequency bands, power bins were summed in δ 0.4-4.3 Hz, θ 4.3-9.8, α 9.8-19.9 Hz, β + γ 19.9-59.8 Hz and expressed in percentage of baseline power band, from the same circadian time. EEG power spectra and frequency bands were also standardized by expressing each frequency bin as a percentage of the total power (0.4-59.8 Hz; Supplementary Fig. 4) .
The individuals performing the saline/CNO injections and sleep-wake analysis did not perform the genotyping or initial immunohistochemical assessment of the injection sites.
Statistical analysis. Statistical analysis was performed using Prism v6 (GraphPad Software). Following confirmation that the data met the assumptions of the ANOVA model, a two-way ANOVA followed by a post hoc Bonferroni test were used to compare the effects of the genotype or the drug injection on sleep-wake parameters. A paired t test was used to compare the effects of drug injection on sleep latencies. Sample size and power calculations were performed post hoc at http://www.biomath.info, using means and s.d. derived from our analysis. Our study was sufficiently powered to detect effect sizes.
Immunohistochemistry. Animals received CNO (0.3 mg per kg, IP, 7 p.m.) and were killed 2 h later by deep anesthesia with 200 mg per kg of chloral hydrate, followed by transcardial perfusion with 20-ml saline, followed by 100 ml of neutral phosphate-buffered formalin (4%, vol/vol, Fischer Scientific). Brains were removed, incubated in 20% sucrose (wt/vol) at 4 °C until they sank, and then sectioned at 40 µm on a freezing microtome in four series. Sections were washed in phosphate-buffered saline (PBS), and incubated in primary antiserum (DsRED (1:10,000) and/or c-Fos (1:20,000); antibody characterization below) diluted in PBS containing 0.3% Triton X-100 (vol/vol, PBST) and 0.2% sodium azide (wt/vol) for 1 d at 20-23 °C. Sections were then washed in PBS and incubated in biotinylated secondary antiserum (against appropriate species IgG, 1:1,000, Vector Laboratories) in PBST for 1 h, washed in PBS and incubated in ABC reagents in PBST for 1 h. Sections were then washed again and incubated in a solution of 0.06% 3,3-diaminobenzidine tetrahydrochloride (DAB, wt/vol, Sigma) and 0.02% H 2 O 2 (vol/vol). The sections were stained brown with DAB or black (c-Fos) by DAB plus 0.05% cobalt chloride (wt/vol) and 0.01% nickel ammonium sulfate (wt/vol).
Antibody characterization. The rabbit polyclonal Fos antibody (Oncogene Sciences, catalog number 4188) was raised against a synthetic peptide including residues 4-17 from human c-Fos. This antibody stained a single band of 55 kDa on western blots from rat brain (manufacturer′s technical information). c-Fos staining with the Ab5 antiserum is found in many CNS structures 45, 46 only when neurons in these structures have recently been physiologically stimulated.
The goat polyclonal antibody against mCherry was raised against DsRED (Clontech, catalog number 632496) and the specificity of immunostaining for DsRED was indicated by the lack of detectable immunostaining in uninjected mice. For all secondary antibody immunohistochemical controls, the primary antibodies were omitted and the tissue showed no immunoreactivity above background.
npg Packaging of dIo-hm3dq and dIo-hm4di AAV. We used the pAAV-hSyn-DIO-hM3Dq-mCherry and pAAV-hSyn-DIO-hM4Di-mCherry plasmids (gift from B. Roth, University of North Carolina at Chapel Hill) to provide the Cre-dependent hM3Dq and hM4Di transgene for packaging into AAV2/10. Packaging was carried out using a standard triple transfection protocol to generate helper virus-free pseudotyped AAV2/10 virus 47 . An AAV 2/10 rep/cap plasmid provided AAV2 replicase and AAV10 capsid functions 48, 49 , and adenoviral helper functions were supplied by the pHelper plasmid (Stratagene). Briefly, AAV-293 cells were transfected via calcium phosphate precipitation with 1.33 pmol of pHelper, and 1.15 pmol each of AAV2/10 and an AAV vector plasmid (double loxP-flanked). The cells were harvested 72 h later and the pellets resuspended in DMEM, freeze-thawed three times and centrifuged to produce a clarified viral lysate. The vector stocks were titered by real-time PCR using an Eppendorf Realplex machine as previously described 50 . The titer of the preparations ranged from approximately 1 × 10 12 to 1 × 10 13 vector genomes copies/ml. In vitro electrophysiology and circuit mapping. 2 weeks after injection of AAV-DIO-ChR2(H134R)-mCherry virus and of retrograde green-fluorescent microspheres, mice were used for the preparation of the PB or BFmc slices for electrophysiological recordings. Mice were anesthetized (ketamine 150 mg per kg and xylazine 15 mg per kg, IP) and transcardially perfused with ice-cold cutting ACSF (N-methyl-D-glucamine, NMDG-based solution) containing (in mM): 119 NMDG-Cl, 2.5 KCl, 1.25 NaH 2 PO 4 , 26 NaHCO 3 , 25 glucose, 2 thiourea, 5 l-ascorbic acid, 3 sodium pyruvate, 0.5 CaCl 2 , 10 MgSO 4 (pH 7.3 with HCl when carbogenated with 95% O 2 and 5% CO 2 ). Their brains were quickly removed and cut in coronal brainstem slices (250 µm thick) in ice-cold cutting ACSF (NMDG-based) using a vibrating microtome (VT1000, Leica). Slices containing the PB or BFmc were transferred in normal ACSF containing (in mM): 124 NaCl, 2.5 KCl, 1.3 MgSO 4 , 10 glucose, 26 NaHCO 3 , 1.24 NaH 2 PO 4 , 4 CaCl 2 (pH 7.4 when carbogenated with 95% O2 and 5% CO2, 310-320 mOsm). We found a large number of neurons retrogradely labeled from the BF in both the ipsilateral lateral and medial PB (LPB and MPB). Infrared differential interference contrast (IR-DIC) visualization of MPB neurons was poorer compared with LPB neurons mainly due to the higher density of myelinated fibers of the MBP, so for this study we focused our recordings on LPB neurons. Recordings were only made from retrogradely labeled neurons (containing the fluorescent microspheres) of the LPB (ipsilateral to the BF and PZ injections) or from retrogradely labeled neurons of the BFmc (ipsilateral to the PFC and lateral PB injections). Recordings were guided using a combination of fluorescence and IR-DIC video microscopy using a fixed stage upright microscope (BX51WI, Olympus America) equipped with a Nomarski water immersion lens (40× / 0.8 W) and IR-sensitive CCD camera (ORCA-ER, Hamamatsu) and images were displayed on a computer screen in real time using AxioVision software (Carl Zeiss MicroImaging). Recordings were conducted in whole-cell configuration using a Multiclamp 700B amplifier (Molecular Devices), a Digidata 1322A interface and Clampex 9.0 software (Molecular Devices). Neurons, axons and synaptic terminals expressing ChR2 were activated by a full-field 2-5-ms flashes of light (~10 mW mm 2 , 1-mm beam width) from a 5-W luxeon blue light-emitted diode (470-nm wavelength, #M470L2-C4; Thorlabs) coupled to the epifluorescence pathway of the Zeiss microscope. Photo-evoked IPSCs in lateral PB neurons were recorded at V h = −5 mV using a cesium methanesulfonate-based pipette solution containing (in mM): 125 cesium methanesulfonate, 11 KCl, 10 HEPES, 0.1 CaCl 2 , 1 EGTA, 5 Mg-ATP and 0.3 Na-GTP (pH adjusted to 7.2 with CsOH, 280 mOsm; Cl − reversal potential = −63 mV). Photo-evoked EPSCs in BFmc neurons were recorded at V h = −60 mV using a potassium gluconate-based pipette solution containing (in mM): 120 potassium gluconate, 10 KCl, 3 MgCl 2 , 10 HEPES, 2.5 K-ATP, 0.5 Na-GTP (pH adjusted to 7.2 with KOH, 280 mOsm). To record photo-evoked synaptic events in the presence of TTX (1 µM), we bath applied the potassium blocker, 4-AP at 1 mM (refs. 52, 53) . Direct responses to photo-stimulation of PZ neurons expressing ChR2 (Supplementary Fig. 7) were recorded using a potassium gluconate-based pipette solution. Electrophysiological data were analyzed using Clampfit 9.0 (Molecular Devices) and IGOR Pro 6 (WaveMetrics). Synaptic events were off-line using Mini Analysis 6 (Synaptosoft). The latency of the photoevoked I/EPSCs was determined by the time difference between the starting of the light pulse and the 5% rise point of the first synaptic event 17 . The probability of any given light pulse evoking a synchronous IPSC was calculated in 50-ms bins and only on the PB neurons responding to photo-stimulation. The area stimulated included the recorded cell, which is in the center of a 500-µm radius concentric field. For all the statistical analyzes we used StatView (SAS Institute). Results are expressed as mean ± s.e.m. and n refers to the number of cells.
A Supplementary methods checklist is available.
